REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board, will present recent progress and 2023 corporate milestones at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 from 11:15 – 11:55 am ET, and that Biomea management will hold 1×1 meetings during the conference January 9 – 11.
A live webcast of the presentation will be available on the Investors & Media page of Biomea’s website at: https://investors.biomeafusion.com/news-events/events.
“2022 was a year of strong execution and fundamental infrastructure build as we transitioned to a clinical-stage company and expanded our pipeline. We enter 2023 with three clinical trials studying BMF-219 across 8 cancer indications covering both blood cancers and solid tumors as well as in Type 2 diabetes, the 7th leading cause of death in the United States,” stated Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board. “We anticipate advancing BMF-500 into the clinic during the first half of 2023, subsequent to FDA clearance of an IND, which will increase our clinical pipeline to 4 clinical trials covering 10 indications. COVALENT-111, our Phase I/II study in Type 2 diabetes is now due to report initial safety and efficacy from the first two cohorts of the Phase II portion by the end of Q1.”
Mr. Butler further commented, “we continue to activate sites and enroll patients in our Phase I/Ib (COVALENT-101) study of BMF-219 in patients with several liquid tumor types, and plan to report initial clinical data from this study in the first half of 2023. In addition, we anticipate initiating dosing imminently in our Phase I/Ib (COVALENT-102) study of BMF-219 in patients with KRAS-mutated solid tumors. In 2023, we will continue the patient-centric urgency and disciplined execution that are now well-established hallmarks of Team Fusion.”
RECENT & ANTICIPATED MILESTONES
ONCOLOGY
COVALENT-101 (BMF-219)
Presented robust anti-tumor activity of covalent menin small molecule inhibitor, BMF-219, as a single agent and mechanistic evidence for novel inhibition of the menin protein in preclinical models of diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). BMF-219 displayed single agent potency, surpassing greater than 90% cell killing at clinically relevant exposures in DLBCL, MM and CLL cell lines and patient-derived samples.
BMF-219 is the first investigational menin inhibitor in clinical development to show potential as a therapeutic agent in hematologic malignancies outside of MLLr and NPM1 mutated acute myeloid leukemia/acute lymphoblastic leukemia (AML/ALL) patients, specifically in subsets of DLBCL, MM and CLL patients.
Biomea continued site activation and patient enrollment for the dosing of BMF-219 across four liquid tumor cohorts in the COVALENT-101 study, including patients with AML/ALL, DLBCL, MM and CLL.
Next Anticipated Milestone:
On track to present initial clinical data of AML/ALL patients (including those with MLL rearrangement and NPM1 mutation) dosed in the COVALENT-101 study in the first half of 2023.
COVALENT-102 (BMF-219)
Presented strong and highly specific pan-KRAS anti-cancer activity of BMF-219 as a single agent across KRAS G12C, G12D, G12V and G13D mutant cell lines including in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and the most prevalent type of pancreatic cancer, PDAC.
BMF-219 is the first investigational menin inhibitor in development to enter clinical trials for the treatment of solid tumors. A targeted pan-KRAS inhibitor could have the potential to treat 25-35% of NSCLC, 35-45% of CRC, and approximately 90% of PDAC patients.
Biomea received FDA clearance of its IND in the fourth quarter of 2022 and has since initiated a Phase I/Ib clinical trial of BMF-219 as a monotherapy in patients who have unresectable, locally advanced, or metastatic NSCLC, CRC or PDAC with an activating KRAS mutation.
Next Anticipated Milestone:
On track to dose first patient in COVALENT-102 study in January 2023.
COVALENT-103 (BMF-500)
Presented data showing multi-fold higher potency and increased cytotoxicity of Biomea’s covalent FLT3 small-molecule inhibitor BMF-500 compared to the commercially available reversible, non-covalent FLT3 inhibitor gilteritinib, and complete, sustained tumor regression in mouse models of FLT3-ITD AML with maintenance of effect after cessation of therapy.
Next Anticipated Milestone:
On track to file IND for BMF-500 in the first half of 2023 to initiate COVALENT-103 study of the covalent FLT3 inhibitor in patients with acute leukemia.
DIABETES
COVALENT-111 (BMF-219)
Presented preclinical data highlighting the ability of BMF-219 in a Type 2 diabetes rat model to restore normal HOMA-B, a measure of pancreatic beta cell function, following only 4-weeks of treatment and to significantly lower HbA1c compared to active control, liraglutide, -3.5% vs -1.7%, respectively.
BMF-219 is the first investigational menin inhibitor in development to enter clinical trials for the improvement of glycemic control and insulin sensitivity in Type 2 diabetes patients.
Biomea completed the healthy volunteer portion of the Phase I/II COVALENT-111 study of BMF-219 in Canada. BMF-219 was well tolerated with an encouraging pharmacokinetic and pharmacodynamic profile in healthy volunteers and with no safety signals detected.
Biomea received FDA clearance in December 2022 to expand the Phase II portion of COVALENT-111 to sites in the U.S. and in January 2023 announced dosing of the first U.S. patient with Type 2 diabetes. The company continues to enroll Type 2 diabetes patients in the Phase II portion of the study in Canada as well.
Next Anticipated Milestones:
On track to present initial clinical data from the first two cohorts of the Phase II portion of the study by the end of Q1 2023, and to present details of the healthy volunteer (Phase I) portion of the study at a scientific medical meeting in 2023.
FUSION™ SYSTEM DISCOVERY PLATFORM
Developed two covalently binding small molecules (BMF-219 and BMF-500), each within 18 months from target identification to IND candidate, leveraging the proprietary FUSION™ System Discovery Platform and showing excellent preclinical profiles.
Next Anticipated Milestone:
On track to announce a third development candidate from the FUSION platform in the first half of 2023.
About Biomea Fusion
Biomea Fusion is a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. The company is utilizing its proprietary FUSION™ System to advance a pipeline of covalent-binding therapeutic agents against key oncogenic drivers of cancer and metabolic diseases. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing covalent small molecules in order to maximize the clinical benefit when treating various cancers and metabolic diseases.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact, including statements regarding the clinical and therapeutic potential of our product candidates and development programs, including BMF-219 and BMF-500, the potential of BMF-500 as an FLT3 inhibitor, the potential of BMF-219 as a treatment for various types of cancer and diabetes, our research, development and regulatory plans, the progress of our ongoing clinical trials, including COVALENT-101, COVALENT-102 and our Phase I/II clinical COVALENT-111 study of BMF-219 in Type 2 diabetes, our plans to present clinical data from our COVALENT-101 study and the first two cohorts of the Phase II portion of our COVALENT-111 study, our plans to dose the first patient in our COVALENT-102 study, our plans to submit an IND application for BMF-500 in patients with FLT3 mutations, our plans to provide clinical updates on the healthy volunteer section of our Phase I/II Type 2 diabetes study of BMF-219, our plans to announce a third development candidate from the FUSION platform, and the timing of such events, may be deemed to be forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions.
Any forward-looking statements in this press release are based on our current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including the risk that we may encounter delays in preclinical or clinical development, the preparation, filing and clearance of INDs, patient enrollment and in the initiation, conduct and completion of our ongoing and planned clinical trials and other research and development activities. These risks concerning Biomea Fusion’s business and operations are described in additional detail in its periodic filings with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent periodic report filed with the SEC and subsequent filings thereafter. Biomea Fusion explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact:
Sasha Blaug
Senior Vice President, Corporate Development
SB@biomeafusion.com
(650) 460-7759
Related Quotes
Takeda Pharmaceutical Co Ltd (NYSE: TAK) and Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced topline results from the Phase 2 SEQUOIA study of fazirsiran (TAK-999/ARO-AAT) for liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD). Patients receiving 25 mg, 100 mg, or 200 mg of fazirsiran who had baseline fibrosis (n=16) demonstrated a dose-dependent mean reduction in serum mutant alpha-1 antitrypsin protein (Z-AAT) concentration at week 48 of 74%, 89%, and 94%, respective
FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.
The price set by the companies is higher than some analyst estimates of about $20,000. "As a result of this higher than expected pricing, we think it is reasonable to see peak sales reach $15.2 billion worldwide," BMO analyst Evan Seigerman said in a research note. However, the price tag is lower than that of Eisai and Biogen's first Alzheimer's disease drug, Aduhelm, which was initially priced at $56,000 annually before the drugmakers halved the price amid controversy over its approval.
The commercial price for the shot is similar to Pfizer’s plans for after government contracting ends.
Neurocrine Biosciences Inc (NASDAQ: NBIX) and Voyager Therapeutics Inc (NASDAQ: VYGR) have formed a new strategic collaboration to advance multiple gene therapies for neurological diseases. Voyager will receive up-front consideration of $175 million, including a $39 million equity investment, up to $1.5 billion in potential development milestones, additional potential commercial milestones, tiered royalties on net sales, program funding, and an option to elect 50/50 cost- and profit-sharing in t
Voyager Therapeutics Inc., the gene therapy startup led by erstwhile Biogen Inc. executive Al Sandrock, has a new deal with a San Diego biotech that's worth up to $4.2 billion.
Last year, the Nasdaq Composite experienced a downturn due to a combination of negative economic and political factors. At any rate, economic issues won't last forever, and the market will eventually continue its march forward. One growth stock that can help with that is none other than DexCom (NASDAQ: DXCM).
Biotech companies are trying to get in front of investors and potential partners — and regulators — with news ahead of the big J.P. Morgan Healthcare Conference in San Francisco.
Ipsen is set to acquire Albireo Pharma Inc., the rare liver disease-focused biopharma spun out of AstraZeneca in 2008, for about $952 million.
With rates rising, biotech has faded. Investors have favored the pharma stalwarts. Bank of America’s drug analyst Geoff Meacham runs through the one’s to watch and a few to avoid. Plus: Could it be another banner year for Devon Energy?
The CEO of the Mass. chapter of the Alzheimer's Association calls the FDA's approval of Leqembi last week "a disease paradigm change."
Sanofi SA (NASDAQ: SNY) elected to terminate its second amended and restated collaboration and license agreement with Regulus Therapeutics Inc (NASDAQ: RGLS), initially announced in 2014. In July 2022, Sanofi decided to terminate the Phase 2 clinical study of lademirsen for Alport syndrome for failure to meet Sanofi’s pre-defined futility criteria. Safety issues forced a revamp of that late-stage program when Sanofi flagged a failure for its microRNA drug lademirsen. At that time, Sanofi was eva
The idea of a big pharmaceutical company set to offer amazing growth might seem unlikely. Pfizer has been around for more than 170 years. Pfizer said in November that in the full year 2022, it expected to generate more than $55 billion in revenue from the two products combined.
Belite Bio (NASDAQ: BLTE), TransMedics Group (NASDAQ: TMDX) and Rhythm Pharmaceuticals (NASDAQ: RYTM) set themselves apart over the past year with triple-digit share price gains. Each of the healthcare companies is developing something unique, whether it be finding treatments for maladies with no approved treatments, a more effective way to do organ transplants, or a more precise way to treat disorders that lead to obesity. Belite Bio is a clinical-stage biopharmaceutical company that focuses on therapies to treat blindness, diabetes, and liver disease.
The FDA grants priority review to Pfizer's (PFE) filing seeking label expansion of its pneumococcal 20-valent conjugate vaccine in infants and children. A decision is expected by this April.
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), continues to pioneer the medical cannabis market in LATAM by announcing that Zerenia has signed a contract with insurance CAPITAL SALUD EPS, to provide medical cannabis services and products to CAPITAL SALUD EPS patient population and has already begun treating the first cohort of patients. Under the contract, CAPITAL SALUD EPS patients will get access to Khiron's products and clinical service
AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline
In this article, we take a look at the 15 most advanced countries in medicine. You can skip our detailed analysis of the healthcare industry and go directly to 5 Most Advanced Countries in Medicine. The recent pandemic was the best reflection of the advancements in the field of medicine. Vaccines were developed at a […]
European drugmakers announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums
After having pancreatic cancer twice, Charles Czajkowski is dedicating the rest of his life to raising awareness of the early symptoms